Cargando…

Targeting MCL-1 in cancer: current status and perspectives

Myeloid leukemia 1 (MCL-1) is an antiapoptotic protein of the BCL-2 family that prevents apoptosis by binding to the pro-apoptotic BCL-2 proteins. Overexpression of MCL-1 is frequently observed in many tumor types and is closely associated with tumorigenesis, poor prognosis and drug resistance. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Haolan, Guo, Ming, Wei, Hudie, Chen, Yongheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061042/ https://www.ncbi.nlm.nih.gov/pubmed/33883020 http://dx.doi.org/10.1186/s13045-021-01079-1

Ejemplares similares

Targeting p53 pathways: mechanisms, structures, and advances in therapy
por: Wang, Haolan, et al.
Publicado: (2023)

Structural basis of the specificity and interaction mechanism of Bmf binding to pro-survival Bcl-2 family proteins
por: Wang, Haolan, et al.
Publicado: (2023)

FGFR-TKI resistance in cancer: current status and perspectives
por: Yue, Sitong, et al.
Publicado: (2021)

Structures of p53/BCL-2 complex suggest a mechanism for p53 to antagonize BCL-2 activity
por: Wei, Hudie, et al.
Publicado: (2023)

Nanomaterials for cancer therapy: current progress and perspectives
por: Cheng, Zhe, et al.
Publicado: (2021)

MCL-1 is a clinically targetable vulnerability in breast cancer
por: Winder, Matthew L, et al.
Publicado: (2022)

Targeting Mcl-1 for Radiosensitization of Pancreatic Cancers()()
por: Wei, Dongping, et al.
Publicado: (2015)

Farnesoid X receptor (FXR): Structures and ligands
por: Jiang, Longying, et al.
Publicado: (2021)

MCL-1 inhibition in cancer treatment
por: Xiang, Weiguo, et al.
Publicado: (2018)

Structural insight into the molecular mechanism of p53-mediated mitochondrial apoptosis
por: Wei, Hudie, et al.
Publicado: (2021)

Inhibitors Targeting YAP in Gastric Cancer: Current Status and Future Perspectives
por: Yong, Jiaxin, et al.
Publicado: (2021)

MCL1 as putative target in pancreatoblastoma
por: Reissig, Timm M., et al.
Publicado: (2022)

Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives
por: Guo, Haiyang, et al.
Publicado: (2022)

Cancer nanotechnology: current status and perspectives
por: Kemp, Jessica A., et al.
Publicado: (2021)

Targeting MCL-1 protein to treat cancer: opportunities and challenges
por: Tantawy, Shady I., et al.
Publicado: (2023)

Targeting cancer stemness mediated by BMI1 and MCL1 for non‐small cell lung cancer treatment
por: Lin, Erh‐Hsuan, et al.
Publicado: (2022)

Finding MicroRNA Targets in Plants: Current Status and Perspectives
por: Ding, Jiandong, et al.
Publicado: (2012)

Targeting Mcl-1 Degradation by Bergenin Inhibits Tumorigenesis of Colorectal Cancer Cells
por: Gan, Yu, et al.
Publicado: (2023)

miR-26a Reverses Multidrug Resistance in Osteosarcoma by Targeting MCL1
por: Li, Ming, et al.
Publicado: (2021)

Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers
por: Lu, Zhihao, et al.
Publicado: (2020)

Current Status and Perspective of Immunotherapy in Gastrointestinal Cancers
por: Kim, Jung Hoon, et al.
Publicado: (2016)

Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants
por: Lin, Qianmeng, et al.
Publicado: (2022)

Corrigendum to: “Farnesoid X receptor (FXR): Structures and ligands” [Comput. Struct. Biotechnol. J. 19 (2021) 2148–2159]
por: Jiang, Longying, et al.
Publicado: (2022)

Molecular perspective on targeted therapy in breast cancer: a review of current status
por: Demir Cetinkaya, Busra, et al.
Publicado: (2022)

Current status and future perspectives in targeted therapy of NPM1-mutated AML
por: Ranieri, Roberta, et al.
Publicado: (2022)

Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment
por: Wang, Zhenguang, et al.
Publicado: (2017)

MCL-1 is a prognostic indicator and drug target in breast cancer
por: Campbell, Kirsteen J., et al.
Publicado: (2018)

PSMA-Targeting Imaging and Theranostic Agents—Current Status and Future Perspective
por: Debnath, Sashi, et al.
Publicado: (2022)

Mcl-1 Ubiquitination and Destruction
por: Inuzuka, Hiroyuki, et al.
Publicado: (2011)

RNA Modifications in Gastrointestinal Cancer: Current Status and Future Perspectives
por: Zhang, Xiaoting, et al.
Publicado: (2022)

Fecal microbiota transplantation in cancer management: Current status and perspectives
por: Chen, Danfeng, et al.
Publicado: (2018)

Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance?
por: Williams, Michelle M., et al.
Publicado: (2015)

Current Status of and Perspectives on Cervical Cancer Screening in Korea
por: Lim, Sung-Chul, et al.
Publicado: (2019)

PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives
por: Musacchio, Lucia, et al.
Publicado: (2020)

N(1)-methyladenosine modification in cancer biology: Current status and future perspectives
por: Li, Jiexin, et al.
Publicado: (2022)

Regulation of Neutrophil Survival/Apoptosis by Mcl-1
por: Milot, Eric, et al.
Publicado: (2011)

Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective
por: Chen, Guoli, et al.
Publicado: (2016)

Structural insight into the ligand binding mechanism of aryl hydrocarbon receptor
por: Dai, Shuyan, et al.
Publicado: (2022)

Structural basis of the farnesoid X receptor/retinoid X receptor heterodimer on inverted repeat DNA
por: Jiang, Longying, et al.
Publicado: (2023)

Current status and perspectives of patient-derived xenograft models in cancer research
por: Lai, Yunxin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_63uup9me6g1752gmmpqnbd4rak